Asklep Inc. (Headquarters: Toshima-ku, Tokyo, Japan, Representative Director and President: Yuichi Yahagi) announced that it has acquired ownership of Kyoto Constella Technologies Co., Ltd. (Nakagyo-ku, Kyoto-shi, Kyoto, Japan, President and CEO: Ryuta Murakami), a long-time business partner, through an increase in holding shares on December 26th, 2016.
Kyoto Constella Technologies is a university spinoff from Kyoto University. Since its creation in March 2008, it has been successfully assisting pharmaceutical companies and research institutions in drug discovery research, and providing a unique service and product using their cutting-edge computational science technology that includes a state-of-the-art database system developed in-house to access adverse drug reaction information.
Asklep and Kyoto Constella Technologies had formed a capital tie-up in May 2015. Our collaborative relationship has further intensified through the expansion of our pharmacovigilance business using their products (CzeekR and CzeekV). The alliance has enabled the expansion across the full scope of our service for drug development from consultation to system development.
With this acquisition, we are determined to further develop the business of Kyoto Constella Technologies to increase the value and stability of services provided. The integration of the “intelligence” of the two companies will enable us to provide better services to the entire drug development process including pharmacovigilance and research.
Asklep offers high value-added medical intelligence through its drug development, post-marketing surveillance and pharmacovigilance services. With our core value of further optimizing the Quality of Life of patients, we strive to enhance the value of medical data and information and deliver highly value-added solutions in the role of Medical Intelligence Provider.
Kyoto Constella Technologies was established in March 2008, as a venture company from Kyoto University. Aiming to support the drug discovery efforts of research institutes and pharmaceutical companies and to develop a database of drug adverse reaction information, we offer products and services based on our core technology developed by Professor Yasushi Okuno of Kyoto University combined with state-of-the-art computational technology.